Patient characteristics
| Characteristics and treatments . | Number . | Percentages . |
|---|---|---|
| Number of patients | 696 | |
| Sex, M/F | 418/278 | 60/40 |
| Median age at transplantation, y (range) | 7 (0.3-17) | |
| Diagnosis | ||
| Malignant disease | 450 | 65 |
| ALL | 268 | 38 |
| AML | 99 | 14 |
| CML | 28 | 5 |
| MDS | 36 | 5 |
| Lymphoma | 19 | 3 |
| Nonmalignant disease | 246 | 35 |
| Thalassemia | 88 | 12 |
| Severe aplastic anemia | 35 | 5 |
| Fanconi anemia | 23 | 3 |
| Immunodeficiencies | 48 | 7 |
| Inborn errors | 52 | 8 |
| Donor | ||
| HLA-identical family donor | 461 | 66 |
| Partially matched family donor | 68 | 10 |
| HLA-identical unrelated donor | 141 | 20 |
| Partially matched unrelated donor | 26 | 4 |
| Female donor/male recipient pairs | 196 | 28 |
| Median donor age, y (range) | 12 (0-55) | |
| Stem cell source | ||
| Bone marrow | 647 | 93 |
| Peripheral blood | 17 | 2 |
| Cord blood | 32 | 5 |
| Conditioning regimen | ||
| Chemotherapy based | 369 | 53 |
| TBI based | 327 | 47 |
| GVHD prophylaxis | ||
| Cs-A | 348 | 50 |
| Cs-A + MTX | 129 | 19 |
| Cs-A + PDN | 63 | 9 |
| Cs-A + MTX + ALG or mAb | 104 | 15 |
| Cs-A + ALG or mAb ± PDN | 33 | 5 |
| T-cell depletion | 19 | 2 |
| Acute GVHD | ||
| Grade 0-I | 406 | 58 |
| Grade II-IV | 290 | 42 |
| Characteristics and treatments . | Number . | Percentages . |
|---|---|---|
| Number of patients | 696 | |
| Sex, M/F | 418/278 | 60/40 |
| Median age at transplantation, y (range) | 7 (0.3-17) | |
| Diagnosis | ||
| Malignant disease | 450 | 65 |
| ALL | 268 | 38 |
| AML | 99 | 14 |
| CML | 28 | 5 |
| MDS | 36 | 5 |
| Lymphoma | 19 | 3 |
| Nonmalignant disease | 246 | 35 |
| Thalassemia | 88 | 12 |
| Severe aplastic anemia | 35 | 5 |
| Fanconi anemia | 23 | 3 |
| Immunodeficiencies | 48 | 7 |
| Inborn errors | 52 | 8 |
| Donor | ||
| HLA-identical family donor | 461 | 66 |
| Partially matched family donor | 68 | 10 |
| HLA-identical unrelated donor | 141 | 20 |
| Partially matched unrelated donor | 26 | 4 |
| Female donor/male recipient pairs | 196 | 28 |
| Median donor age, y (range) | 12 (0-55) | |
| Stem cell source | ||
| Bone marrow | 647 | 93 |
| Peripheral blood | 17 | 2 |
| Cord blood | 32 | 5 |
| Conditioning regimen | ||
| Chemotherapy based | 369 | 53 |
| TBI based | 327 | 47 |
| GVHD prophylaxis | ||
| Cs-A | 348 | 50 |
| Cs-A + MTX | 129 | 19 |
| Cs-A + PDN | 63 | 9 |
| Cs-A + MTX + ALG or mAb | 104 | 15 |
| Cs-A + ALG or mAb ± PDN | 33 | 5 |
| T-cell depletion | 19 | 2 |
| Acute GVHD | ||
| Grade 0-I | 406 | 58 |
| Grade II-IV | 290 | 42 |